![[Ir(cod)Cl]2 (Chloro-1,5-cyclooctadiene iridium(I) dimer)](/upload/1124/V68658.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| Targets |
[Ir(cod)Cl]2 does not have a biological target. It is a catalyst precursor used in organic synthesis for chemical transformations. The compound is not pharmacologically active and is not used as a therapeutic agent. Its applications are in chemical synthesis, including the synthesis of pharmaceutical intermediates.
|
|---|---|
| ln Vitro |
In several cases, [Ir(cod)Cl]2 is employed as a precursor to other iridium complexes for homogeneous catalysis, including chirality catalytic reactions, asymmetric allylic substitution, carbonylation, hydrosilylation, and hydroformylation. It is used in the process of making Crabtree catalysts, which are used in hydrogenation and hydrogen transfer reactions.
[Ir(cod)Cl]2 is not used in cell-based assays. It is a catalyst precursor for chemical reactions and is not tested for biological activity in vitro. The compound is used to synthesize compounds that may subsequently be tested for biological activity, but the catalyst itself is not a test compound. |
| ln Vivo |
[Ir(cod)Cl]2 is not administered to animals. It is a catalyst precursor used in chemical synthesis and is not a therapeutic agent. The compound is not used in in vivo studies.
|
| Enzyme Assay |
[Ir(cod)Cl]2 is not used in enzyme/receptor binding assays. It is a catalyst precursor for organic synthesis, not a biologically active compound. The compound is used to prepare iridium complexes for catalytic applications such as chiral catalysis and asymmetric allylic substitution.
|
| Cell Assay |
[Ir(cod)Cl]2 is not used in cell-based assays. It is a catalyst precursor for chemical synthesis and is not tested for biological activity. The compound may be used to synthesize compounds that are subsequently tested in cellular systems, but the catalyst itself is not a test compound.
|
| Animal Protocol |
[Ir(cod)Cl]2 is not used in animal studies. It is a catalyst precursor for chemical synthesis and is not a therapeutic agent. The compound is not administered to animals.
|
| ADME/Pharmacokinetics |
[Ir(cod)Cl]2 is a chemical catalyst precursor and is not subject to pharmacokinetic evaluation. Its physicochemical properties include a molecular weight of 671.702 g/mol and a molecular formula of C16H24Cl2Ir2. The compound is stable under normal storage conditions and should be handled under inert atmosphere. It is soluble in organic solvents.
|
| Toxicity/Toxicokinetics |
The toxicological profile of [Ir(cod)Cl]2 has not been extensively characterized. As an iridium complex, it may pose health hazards, including skin, eye, and respiratory tract irritation. Standard laboratory safety precautions should be observed, including the use of personal protective equipment (gloves, goggles, lab coat) and adequate ventilation. Ingestion or inhalation should be avoided.
|
| Additional Infomation |
[Ir(cod)Cl]2 is not a drug but a valuable catalyst precursor for organic synthesis and drug discovery. It serves as a versatile precursor to a wide range of iridium complexes used in homogeneous catalysis, including chiral catalysis and asymmetric allylic substitution. It is used as a biochemical reagent for life science research and as a sulfonylation reagent. It is not approved for clinical use.
|
| Molecular Formula |
C20H36CL2IR2
|
|---|---|
| Molecular Weight |
731.84
|
| Exact Mass |
672.051
|
| CAS # |
12112-67-3
|
| PubChem CID |
6436381
|
| Appearance |
Orange to red solid powder
|
| Boiling Point |
153.5ºC at 760 mmHg
|
| Melting Point |
205 °C (dec.)(lit.)
|
| Flash Point |
31.7ºC
|
| Vapour Pressure |
4.25mmHg at 25°C
|
| LogP |
6.724
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
20
|
| Complexity |
72.6
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1/C=C\CC/C=C\C1.C1/C=C\CC/C=C\C1.[Cl-].[Cl-].[Ir].[Ir]
|
| InChi Key |
SHZHQWGWORCBJK-MIXQCLKLSA-L
|
| InChi Code |
InChI=1S/2C8H12.2ClH.2Ir/c2*1-2-4-6-8-7-5-3-1;;;;/h2*1-2,7-8H,3-6H2;2*1H;;/p-2/b2*2-1-,8-7-;;;;
|
| Chemical Name |
(1Z,5Z)-cycloocta-1,5-diene;iridium;dichloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (136.64 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 10 mg/mL (13.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 10 mg/mL (13.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3664 mL | 6.8321 mL | 13.6642 mL | |
| 5 mM | 0.2733 mL | 1.3664 mL | 2.7328 mL | |
| 10 mM | 0.1366 mL | 0.6832 mL | 1.3664 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
